Fluoroquinolone Antibiotics and Tendon Injury in Adolescents

Author:

Ross Rachael K.1,Kinlaw Alan C.23,Herzog Mackenzie M.45,Jonsson Funk Michele1,Gerber Jeffrey S.67

Affiliation:

1. Department of Epidemiology, Gillings School of Global Public Health,

2. Division of Pharmaceutical Outcomes and Policy, School of Pharmacy,

3. The Cecil G. Sheps Center for Health Services Research, and

4. IQVIA, Durham, North Carolina;

5. Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;

6. Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; and

7. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Abstract

OBJECTIVES: To estimate the association between fluoroquinolone use and tendon injury in adolescents. METHODS: We conducted an active-comparator, new-user cohort study using population-based claims data from 2000 to 2018. We included adolescents (aged 12–18 years) with an outpatient prescription fill for an oral fluoroquinolone or comparator broad-spectrum antibiotic. The primary outcome was Achilles, quadricep, patellar, or tibial tendon rupture identified by diagnosis and procedure codes. Tendinitis was a secondary outcome. We used weighting to adjust for measured confounding and a negative control outcome to assess residual confounding. RESULTS: The cohort included 4.4 million adolescents with 7.6 million fills for fluoroquinolone (275 767 fills) or comparator (7 365 684) antibiotics. In the 90 days after the index antibiotic prescription, there were 842 tendon ruptures and 16 750 tendinitis diagnoses (crude rates 0.47 and 9.34 per 1000 person-years, respectively). The weighted 90-day tendon rupture risks were 13.6 per 100 000 fluoroquinolone-treated adolescents and 11.6 per 100 000 comparator-treated adolescents (fluoroquinolone-associated excess risk: 1.9 per 100 000 adolescents; 95% confidence interval −2.6 to 6.4); the corresponding number needed to treat to harm was 52 632. For tendinitis, the weighted 90-day risks were 200.8 per 100 000 fluoroquinolone-treated adolescents and 178.1 per 100 000 comparator-treated adolescents (excess risk: 22.7 per 100 000; 95% confidence interval 4.1 to 41.3); the number needed to treat to harm was 4405. CONCLUSIONS: The excess risk of tendon rupture associated with fluoroquinolone treatment was extremely small, and these events were rare. The excess risk of tendinitis associated with fluoroquinolone treatment was also small. Other more common potential adverse drug effects may be more important to consider for treatment decision-making, particularly in adolescents without other risk factors for tendon injury.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Reference53 articles.

1. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015;Lovegrove;J Pediatric Infect Dis Soc,2019

2. Adverse drug reactions in children: the double-edged sword of therapeutics;Elzagallaai;Clin Pharmacol Ther,2017

3. US Food and Drug Administration. Drug research and children. 2016. Available at: https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143565.htm. Accessed March 1, 2019

4. Lessons learned in antibiotic stewardship: fluoroquinolone use in pediatrics;Hersh;J Pediatric Infect Dis Soc,2015

5. Safety concerns surrounding quinolone use in children;Patel;J Clin Pharmacol,2016

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3